The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106

Molecular Cancer Therapeutics

Volumn 9, Issue 1, 2010, Pages 89-100

  Walton, Michael I ^a   Eve, Paul D ^a   Hayes, Angela ^a   Valenti, Melanie ^a   Brandon, Alexis De Haven ^a   Box, Gary ^a   Boxall, Kathy J ^a   Aherne, G Wynne ^a   Eccles, Suzanne A ^a   Raynaud, Florence I ^a   Williams, David H ^b   Reader, John C ^b   Collins, Ian ^a   Garrett, Michelle D ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b Sareum Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE 1; ETOPOSIDE; GEMCITABINE; HISTONE H2AX; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOCODAZOLE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; SAR 020106; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL STRAIN A 2780; CELL STRAIN COLO 205; CELL STRAIN HT29; CELL STRAIN SW 620; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENZYME ASSAY; HUMAN; HUMAN CELL; IC 50; MITOSIS INHIBITION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL DEATH; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA DAMAGE; DRUG SYNERGISM; G2 PHASE; HUMANS; ISOQUINOLINES; MICE; MICE, NUDE; MUTAGENS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZINES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73949130389     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0938     Document Type: Article

References (48)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
2. Zhou BB, Elledge SJ. The DNA damage response:putting checkpoints in perspective. Nature 2000;408:433-9.
3. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999;274:36031-4.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancer. Science 1991;253:49-53.
5. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008;98: 523-8.
6. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3:513-9.
7. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumor cells. Nat Rev Cancer 2004;4:592-9.
8. Abraham RT. Cell cycle checkpoint signalling through the ATM and ATR kinases. Genes Dev 2001;15:2177-96.
9. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human CHK1. Mol Cell Biol 2001;21:4129-39.
10. Guo ZJ, Kmagai A, Wang SX, Dunphy WG. Requirement for ATR in phosphorylation of CHK1 and cell cycle regulation in response to DNA replication blocks and UV-damage in Xenopus egg extracts. Genes Dev 2000;14:2745-56.
11. Smits VAJ. Spreading the signal-dissociation of CHK1 from chromatin. Cell Cycle 2006;5:1039-43.
12. Clarke CA, Clarke PR. DNA-dependent phosphorylation of CHK1 and claspin in human cell-free system. Biochem J 2005;388: 705-12.
13. Feijoo C, Hall-Jackson C, Wu R, et al. Activation of a mammalian CHK1 during DNA replication arrest: role of CHK1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001;154:913-23.
14. 2 arrests through CDC25A degradation in response to DNA-damaging agents. J Biol Chem 2003;278:21767-73.
15. 2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of CDC25C on serine 216. Science 1997;277:1501-5.
16. Lee SI, Brown MK, Eastman A. Comparison of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem Pharmacol 1999;58:1713-21.
17. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-65.
18. Graves PR, Yu L, Schwarz JK, et al. The CHK1 protein kinase and the CDC25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275:5600-5.
19. Ganzinelli M, Carrassa L, Crippa F, Tavecchio M, Broggini M, Damia G. Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res 2008; 14:5131-41.
20. Janetka JW, Ashwell S, Zabludoff S, Lyne P. Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Devel 2007;10:473-86.
21. Tse AN, Carvajal R, Scwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007;13:1955-60.
22. Park JW, Kerbel RS, Kelloff GJ, et al. Rationale for biomarkers and surrogate end points in mechanism driven oncology drug development. Clin Cancer Res 2004;10:3885-96.
23. Workman P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic end points in contemporary drug discovery and development. Curr Pharm Des 2003;9:891-902.
24. Zabludoff SD, Grondine MR, Sheehy AM, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008;7: 2955-66.
25. Blasina A, Hallin J, Chen E, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008;7:2394-404.
26. Tse AN, Rendahl KG, Sheikh T, et al. CHIR-124, a novel potent inhibitor of CHK1, potentiates the cytotoxicity of topoisomerase 1 poisons in vitro and in vivo. Clin Cancer Res 2007;13:591-602.
27. Matthews DJ, Yakes FM, Chen J, et al. Pharmacological abrogation of S-phase checkpoints enhances the antitumor activity of gemcitabine in vivo. Cell Cycle 2007;6:104-10.
28. Wang GT, Gaoquan L, Mantei RA, et al. 1(5-Chloro-2-alkoxyphenyl)-3-(5- cyano-pyrazi-2-yl) ureas as potent and selective inhibitors of CHK1 kinase: synthesis, preliminary SAR, and biological activities. J Med Chem 2005;48:3118-21.
29. Collins I, Reader JC, Williams DH, et al. Int Pat Appl WO 103966, 2009. Chem Abstr 2009;151:1042183.
30. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 2000;57:503-11.
31. Matthews TP, Klair S, Burns S, et al. Identification of inhibitors of checkpoint kinase 1 through template screening. J Med Chem 2009;52:4810-9.
32. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82: 1107-12.
33. Gowan SM, Hardcastle A, Hallsworth AE, et al. Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. Assays Drug Dev Technol 2007;5: 391-401.
34. Wilson GD. Analysis of DNA-measurements of cell kinetics by the bromodeoxyuridine/antibromodeoxyuridine method. In: Ormerod MG, editor. Flow Cytometry (2nd Edition): A practical approach. Oxford: IRL Press; 1994, p. 137-56.
35. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J. United Kingdom co-ordinating committee on cancer research guidelines for the welfare of animals in experimental neoplasia. 2nd ed. Br J Cancer 1998;77:1-10.
36. Watanabe N, Broome M, Hunter T. Regulation of the human WEE1-Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 1995;14: 1878-91.
37. Wang Y, Li J, Booher RN, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator. Cancer Res 2001;61:8211-7.
38. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-strand breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
39. Gobeil S, Boucher CC, Nadeau D, Poirier GG. Characterization of the necrotic cleavage of poly (ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Diff 2001;8:588-94.
40. Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat Rev Cancer 2007;7:925-36.
41. Shapiro GI. Cyclin dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
42. Pommier Y. Topoisomerase 1 inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
43. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007;6:1239-48.
44. Petermann E, Caldecott KW. Evidence that the ATR/CHK1 pathway maintains normal replication fork progression during unperturbed S phase. Cell Cycle 2006;5:2203-9.
45. Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 2006;5:1983-8.
46. Xiao Z, Xue J, Gu W-Z, et al. Cyclin B1 is an efficacy-predicting biomarker for CHK1 inhibitors. Biomarkers 2008;13:579-96.
47. Parsels LA, Morgan MA, Tanska DM, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009;8:45-54.
48. Takai H, Tominaga K, Motoyama N. Aberrant cell cycle checkpoint function and early embryonic death in CHK1(-/-) mice. Genes Dev 2000;14:1439-47.